title: Severe autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia responsive to fludarabine-based treatment.
authors.forename: S
authors.initials: S
authors.lastname: Tosti
authors.forename: R
authors.initials: R
authors.lastname: Caruso
authors.forename: F
authors.initials: F
authors.lastname: D'Adamo
authors.forename: A
authors.initials: A
authors.lastname: Picardi
authors.forename: M
authors.initials: M
authors.lastname: Ali Ege
authors.forename: G
authors.initials: G
authors.lastname: Girelli
authors.forename: F R
authors.initials: FR
authors.lastname: Mauro
authors.forename: L
authors.initials: L
authors.lastname: Maurillo
authors.forename: S
authors.initials: S
authors.lastname: Amadori
mesh_terms: D000744:Anemia, Hemolytic, Autoimmune / Q000139:chemically induced*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine